Search

everythinglearnresearchcommunity

for

Search:↓

Promising treatments for EBS include anti-inflammatory drugs, antibiotics, creams, mTOR inhibitors, and gene editing, but more trials are needed.

The document concludes that DNA methylation and the mTOR pathway are important for stem cell function and could impact disease treatment.

Anti-complement agents could effectively treat autoimmune diseases with fewer side effects.

The document concludes that reactivation of herpesviruses, especially HHV-6, is linked to severe symptoms and complications in drug-induced hypersensitivity syndrome.

Rabies vaccine might cause hair loss due to immune issues.

Advancements in dermatology are improving diagnosis, treatment options, and patient care.

Newborn screening and gene therapy are expected to improve outcomes for Omenn syndrome patients.

Some patients on immune therapy for melanoma may develop scarring hair loss, but cancer treatment remains effective.

Immune cells might contribute to hair loss caused by a specific mutation.

The study suggests a link between varicella-zoster virus and segmental vitiligo, with evidence of the virus disrupting skin pigment cells.

Microneedle patches offer painless, effective drug delivery and are suitable for all ages.

Virus infection risk is linked to heat tolerance and size, but decreases with high humidity and mutation rates.

Early intervention with JAK inhibitors may prevent alopecia areata progression.

EV-based drug delivery shows promise but faces challenges in standardization and scalability.

Most HIV patients develop skin symptoms that can indicate the stage of their disease.

A young boy with Netherton syndrome improved significantly using IVIG, dupilumab, and dietary changes.

New partnerships, clinical trials, and drug approvals marked progress in therapeutic delivery in July 2018.

Nanoparticle-embedded microneedles improve drug delivery through the skin but face challenges in stability and safety.

Unregulated exosome-based injections can cause severe skin reactions and scarring.

IVIG and dupilumab effectively improved symptoms in a child with Netherton syndrome.

Dual-targeting therapies like Janus kinase inhibitors may treat both alopecia areata and other immune diseases.

Hedgehog pathway inhibitors can treat certain aggressive cancers but face limitations like resistance and side effects.

Topical contact sensitizers can treat certain skin conditions by changing the immune response.

IVIG therapy significantly improved symptoms in a patient with APS-2 and SPS.

The targeted nanohybrids effectively reduced psoriasis symptoms and improved skin health.

Poly(ADP-ribose) synthesis is linked to skin cell differentiation.

Immunotherapy for cancer caused a patient to develop a condition affecting hormone production, requiring ongoing hormone replacement therapy.

These new skin treatments are safer and more effective with minimal side effects.

Poor response to topical immunotherapy in alopecia areata patients is linked to impaired cell responses.

A man with four autoimmune diseases suggests a new category for multiple autoimmune syndrome.